The Role of Vancomycin in the Treatment Paradigm
Open Access
- 1 January 2006
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 42 (Supplement), S51-S57
- https://doi.org/10.1086/491714
Abstract
Vancomycin was introduced in the United States in 1956 as a possible treatment for infections due to penicillin-resistant Staphylococcus aureus, butKeywords
This publication has 40 references indexed in Scilit:
- Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep, Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant StrainsClinical Infectious Diseases, 2006
- Treatment of Vancomycin-intermediate Staphylcoccus aureus Endocarditis with LinezolidScandinavian Journal of Infectious Diseases, 2004
- Relationship of MIC and Bactericidal Activity to Efficacy of Vancomycin for Treatment of Methicillin-Resistant Staphylococcus aureus BacteremiaJournal of Clinical Microbiology, 2004
- Endocarditis Caused byStaphylococcus aureuswith Reduced Susceptibility to VancomycinClinical Infectious Diseases, 2004
- Staphylococcus aureus BacteremiaMedicine, 2003
- Vancomycin for Staphylococcus aureus endocarditis in intravenous drug usersAntimicrobial Agents and Chemotherapy, 1990
- Combination Antimicrobial Therapy forStaphylococcus aureusEndocarditis in Patients Addicted to Parenteral Drugs and in NonaddictsAnnals of Internal Medicine, 1982
- Vancomycin Therapy for Infective EndocarditisClinical Infectious Diseases, 1981
- VancomycinPublished by American Medical Association (AMA) ,1977
- Antimicrobial Therapy of Experimental Endocarditis Caused by Staphylococcus aureusThe Journal of Infectious Diseases, 1975